News
-
DIZH Rapid-Action-Call: Funded projects
16 Projects are being funded in the 4th Rapid-Action-Call of the DIZH Innovationsprogramms
-
metaLead funded by the UZH Life Science Fund
The UZH Life Science Fund awards CHF 1 million for metaLead
-
Patent Index 2024: Switzerland leads patent applications per capita
Switzerland demonstrates its innovative prowess, ranking fist in Europe for patents per capita, according to the Patent Index 2024 from
-
New Spin-Offs with Innovative Technology
Six new spin-offs were founded last year, in which research results of UZH have been incorporated
-
1st Swiss Academic Innovation and Entrepreneurship Forum
To promote innovation and entrepreneurship at Swiss Academic Institutions participants from all over Switzerland gathered
-
University of Zurich Spin-off revolutionizes translation industry with AI
Following its merger with University of Zurich spin-off TextShuttle, Zurich-based Supertext has launched a new AI-powered
-
New @UZH: GET-a-MATCH
Co-founder or projectsupporter needed? Get a match by publishing an ad on GET-a-MATCH!
UZH News shed light on the critical issues of our time with research that contributes to forward-looking solutions for our society – below the UZH news focusing on innovation:
-
Fast, Painless, Precise: New Urine Test for Prostate Cancer Screening
In the future, a simple urine test could detect early-stage prostate cancer. In this interview, the developers tell the story of their invention.
-
A Giant Step that Heralds a New Space Age
On board the private spaceflight mission Fram2, the Space Genomics experiment of the University of Zurich launched today.
-
Efficient Development of Drugs with Fewer Mice
With a novel technology, around 25 antibodies can now be tested simultaneously in a single mouse. This should speed up the R&D pipeline for new drugs and hugely reduce the number of animals required.
-
Promising Active Ingredient for Lupus Therapy
In lupus, the immune system attacks its own structures, causing inflammation and organ damage. A UZH study shows that natural active ingredient gluconolactone could offer a more targeted therapy.